市場調查報告書
商品編碼
1085275

全球生物製藥市場:藥物類別、治療用途、分銷渠道、區域規模、份額、前景、機會分析(2022-2028)

Biologics Market, by Drug Class, by Therapeutic Application, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 317 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

新的生物製藥產品在市場上的快速批准和上市預計將成為生物製藥市場增長的主要增長因素。然而,用於治療類風濕性關節炎、癌症、多發性硬化症、牛皮癬和其他疾病的生物製藥的高成本預計將阻礙預測期內生物製藥市場的增長。

本報告調查全球生物製藥市場,並提供有關市場前景、市場動態、市場分析、競爭條件等方面的全面信息。

目錄

第 1 章調查目標/先決條件

  • 調查目的
  • 假設
  • 縮寫

第2章市場概述

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
    • 市場細分:按藥物類別
    • 市場細分:按治療用途
    • 市場細分:按分銷渠道
    • 市場細分:按地區
  • 連貫的機會圖 (COM)

第3章市場動態、監管和趨勢分析

  • 市場動態
    • 促進因素
    • 抑制器
    • 市場機會
  • 生物製藥和生物仿製藥概述
  • 影響分析
  • 專利到期日分析
  • 管道分析
  • 監管場景
  • 兌換場景
  • 產品批准/發布
  • 協作-收購
  • 市場趨勢
  • PEST 分析
  • 流行病學

第 4 章全球生物製藥市場:按藥物類別(10 億美元)(2017-2028 年)

  • 簡介
  • 單克隆抗體
  • 疫苗
  • 重組胰島素
  • 人類生長激素
  • 血液因子
  • 融合蛋白
  • 促紅細胞生成素
  • 干擾素
  • 轉基因□
  • 菌落刺激因子
  • 細胞療法
  • 基因治療
  • 寡核甘酸
  • 其他(□、肉毒桿菌毒素等)

第 5 章全球生物製藥市場:按治療用途(10 億美元)(2017-2028 年)

  • 簡介
  • 腫瘤
  • 代謝紊亂
  • 自身免疫性疾病/免疫性疾病
  • 眼病
  • 炎症性腸病 (IBD)
  • 呼吸系統疾病
  • 神經系統疾病
  • 肌肉骨骼疾病
  • 心血管疾病
  • 傳染病
  • 其他

第 6 章全球生物製藥市場:按分銷渠道(10 億美元)(2017-2028)

  • 簡介
  • 醫院藥房
  • 零售藥店
  • 網上藥店

第 7 章全球生物製藥市場:區域(10 億美元)(2017-2028)

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 非洲
  • 中東

第8章競爭態勢

  • 公司簡介
    • Bristol-Myers Squibb Company(BMS)
    • Merck &Co., Inc.
    • Roche AG
    • Merck KGaA
    • AstraZeneca Plc
    • Regeneron Pharmaceuticals, Inc
    • Novartis International AG
    • Pfizer, Inc.
    • Amgen, Inc.
    • AbbVie, Inc.
    • Sanofi SA
    • Eli Lilly &Company
    • Novo Nordisk A/S
    • Johnson &Johnson
    • GlaxoSmithKline Plc
    • Teva Pharmaceutical Industries Ltd.
    • Ipsen SA
    • Allergan Plc.

第9章 部門

目錄
Product Code: CMI2663

Biological products include wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for the treatment of genetic disorders. Biologics are also used to treat children with CLN2 disease, which is a form of Batten disease. Moreover, in 2017, BioMarin Pharmaceutical Inc. received the U.S. FDA approval for its Brineura (cerliponase alfa), which is indicated for the treatment CLN2 disease.

Market Dynamics

In the recent past, several novel biopharmaceutical products were approved by major regulatory bodies and major players in the market have launched various novel and innovative biopharmaceutical products. Rapid approvals and launches of novel products in the market are expected to be major drivers for growth of the biologics market. For instance, in 2017, Amgen Inc. received the U.S. Food and Drug Administration (FDA) for its Blincyto (Blinatumomab) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.

Furthermore, in 2017, Janssen Biotech, Inc. received the U.S FDA approval for Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma.

However, high cost of biologics for the treatment of diseases such as rheumatoid arthritis, cancer, multiple sclerosis, psoriasis, and other diseases is expected to hamper biologics market growth over the forecast period. For instance, according to the data published in NCBI in 2018, the cost of biologics for treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases can range from US$ 10,000 to US$ 30,000 per year in the U.S. and can exceed US$ 500,000 per year for the most expensive biologics.

Furthermore, it is more difficult to manufacture biologics than chemical drugs, as they are extremely sensitive due to its very complex molecules.

Key features of the study:

This report provides in-depth analysis of the global biologics market, market size (US$ Bn), and compound annual growth rate (CAGR (%) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the global biologics market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies

Key players covered as a part of this study include Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc.

Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

The global biologics market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for Global Biologics Market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Biologics Market, by Drug Class:

Monoclonal Antibody

Vaccine

Recombinant Insulin

Human Growth Hormone

Blood Factor

Fusion Protein

Erythropoietin

Recombinant Enzyme

Interferon

Colony-stimulating Factor

Cell Therapy

Gene Therapy

Oligonucleotides

Others

Global Biologics Market, By Therapeutic Application:

Oncology

Metabolic Disorders

Autoimmune/Immunologic Diseases

Ophthalmic Diseases

Inflammatory Bowel Diseases (IBDs)

Respiratory Disorders

Neurological Disorders

Musculoskeletal Disorders (MSDs)

Cardiovascular Diseases (CVDs)

Infectious Diseases

Others

Global Biologics Market, by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Biologics Market, by Region:

North America

By Country:

U.S.

Canada

By Drug Class:

Monoclonal Antibody

Vaccine

Recombinant Insulin

Human Growth Hormone

Blood Factor

Fusion Protein

Erythropoietin

Recombinant Enzyme

Interferon

Colony-stimulating Factor

Gene Therapy

Cell Therapy

Oligonucleotides

Others

By Therapeutic Application:

Oncology

Metabolic Disorders

Autoimmune/Immunologic Diseases

Ophthalmic Diseases

Inflammatory Bowel Diseases (IBDs)

Respiratory Disorders

Neurological Disorders

Musculoskeletal Disorders (MSDs)

Cardiovascular Diseases (CVDs)

Infectious Diseases

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Europe

By Country:

U.K.

Germany

Italy

Spain

France

Russia

Rest of Europe

By Drug Class:

Monoclonal Antibody

Vaccine

Recombinant Insulin

Human Growth Hormone

Blood Factor

Fusion Protein

Erythropoietin

Recombinant Enzyme

Interferon

Colony-stimulating Factor

Gene Therapy

Cell Therapy

Oligonucleotides

Others

By Therapeutic Application:

Oncology

Metabolic Disorders

Autoimmune/Immunologic Diseases

Ophthalmic Diseases

Inflammatory Bowel Diseases (IBDs)

Respiratory Disorders

Neurological Disorders

Musculoskeletal Disorders (MSDs)

Cardiovascular Diseases (CVDs)

Infectious Diseases

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Asia Pacific

By Country:

Australia

India

China

Japan

ASEAN

South Korea

Rest of Asia Pacific

By Drug Class:

Monoclonal Antibody

Vaccine

Recombinant Insulin

Human Growth Hormone

Blood Factor

Fusion Protein

Erythropoietin

Recombinant Enzyme

Interferon

Colony-stimulating Factor

Gene Therapy

Cell Therapy

Oligonucleotides

Others

By Therapeutic Application:

Oncology

Metabolic Disorders

Autoimmune/Immunologic Diseases

Ophthalmic Diseases

Inflammatory Bowel Diseases (IBDs)

Respiratory Disorders

Neurological Disorders

Musculoskeletal Disorders (MSDs)

Cardiovascular Diseases (CVDs)

Infectious Diseases

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Latin America

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

By Drug Class:

Monoclonal Antibody

Vaccine

Recombinant Insulin

Human Growth Hormone

Blood Factor

Fusion Protein

Erythropoietin

Recombinant Enzyme

Interferon

Colony-stimulating Factor

Gene Therapy

Cell Therapy

Oligonucleotides

Others

By Therapeutic Application:

Oncology

Metabolic Disorders

Autoimmune/Immunologic Diseases

Ophthalmic Diseases

Inflammatory Bowel Diseases (IBDs)

Respiratory Disorders

Neurological Disorders

Musculoskeletal Disorders (MSDs)

Cardiovascular Diseases (CVDs)

Infectious Diseases

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Middle East

By Country:

GCC

Israel

Rest of Middle East

By Drug Class:

Monoclonal Antibody

Vaccine

Recombinant Insulin

Human Growth Hormone

Blood Factor

Fusion Protein

Erythropoietin

Recombinant Enzyme

Interferon

Colony-stimulating Factor

Gene Therapy

Cell Therapy

Oligonucleotides

Others

By Therapeutic Application:

Oncology

Metabolic Disorders

Autoimmune/Immunologic Diseases

Ophthalmic Diseases

Inflammatory Bowel Diseases (IBDs)

Respiratory Disorders

Neurological Disorders

Musculoskeletal Disorders (MSDs)

Cardiovascular Diseases (CVDs)

Infectious Diseases

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Africa

By Country/Region:

South Africa

Central Africa

North Africa

By Drug Class:

Monoclonal Antibody

Vaccine

Recombinant Insulin

Human Growth Hormone

Blood Factor

Fusion Protein

Erythropoietin

Recombinant Enzyme

Interferon

Colony-stimulating Factor

Gene Therapy

Cell Therapy

Oligonucleotides

Others

By Therapeutic Application:

Oncology

Metabolic Disorders

Autoimmune/Immunologic Diseases

Ophthalmic Diseases

Inflammatory Bowel Diseases (IBDs)

Respiratory Disorders

Neurological Disorders

Musculoskeletal Disorders (MSDs)

Cardiovascular Diseases (CVDs)

Infectious Diseases

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Company Profiles

Bristol-Myers Squibb Company (BMS) *

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

Merck & Co., Inc.

Roche AG

Merck KGaA

AstraZeneca Plc

Regeneron Pharmaceuticals, Inc

Novartis International AG

Pfizer, Inc.

Amgen, Inc.

AbbVie, Inc.

Sanofi S.A.

Eli Lilly & Company

Novo Nordisk A/S

Johnson & Johnson

GlaxoSmithKline Plc

Teva Pharmaceutical Industries Ltd.

Ipsen S.A.

Allergan Plc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Therapeutic Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Biologics & Biosimilars Overview
  • Impact Analysis
  • Patent Expiry Analysis
  • Pipeline Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • Product Approval/Launch
  • Collaboration-Acquisition
  • Market Trends
  • PEST Analysis
  • Epidemiology

4. Global Biologics Market, By Drug Class, 2017 - 2028, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Monoclonal Antibody
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Vaccine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Recombinant Insulin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Human Growth Hormone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Blood Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Fusion Protein
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Erythropoietin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Interferon
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Recombinant Enzyme
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Colony-stimulating Factor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Cell Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Oligonucleotides
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Others (Peptide, Botulinum Toxin, and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)

5. Global Biologics Market, By Therapeutic Application, 2017 - 2028, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Metabolic Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Autoimmune/Immunologic Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Ophthalmic Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Inflammatory Bowel Diseases (IBDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Respiratory Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Neurological Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Musculoskeletal Disorders (MSDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Cardiovascular Diseases (CVDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Infectious Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)

6. Global Biologics Market, By Distribution Channel, 2017 - 2028, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)

7. Global Biologics Market, By Region, 2017 - 2028 (US$ Billion)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Billion)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Billion)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Billion)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Billion)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Billion)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Bristol-Myers Squibb Company (BMS)
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Roche AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck KGaA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Regeneron Pharmaceuticals, Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Amgen, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AbbVie, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Eli Lilly & Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novo Nordisk A/S
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Ipsen S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Allergan Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact